Three phase 3 studies of brolucizumab in patients with retinal diseases will be terminated early after more frequent dosing intervals were associated with higher rates of intraocular inflammation, Novartis announced.
The MERLIN study and the RAPTOR and RAVEN studies, whose methods all include periods of 4-week dosing intervals of Beovu (brolucizumab), will be stopped. And, “All other relevant ongoing trial protocols will be amended to discontinue 4-week dosing intervals after the loading phase,” a company press release said.
In reporting 1-year results of the 2-year MERLIN study of